- Allergan (AGN -0.7%) prevails in its patent infringement litigation with Novartis' (NVS +1.8%) Sandoz unit related to glaucoma med COMBIGAN (brimonidine tartrate/timolol maleate ophthalmic solution).
- A New Jersey judge ruled that Sandoz's marketing application seeking approval for a generic version infringes on a composition of matter patent that expires in 2022.
- Allergan lost an earlier case with Sandoz related to three other COMBIGAN patents.
- Source: Bloomberg